Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.

P J Stiff, D Sweet, L J Kilton, C M Johnson, B Muntean, R R Blough

Index: Med. Pediatr. Oncol. 19(2) , 126-8, (1991)

Full Text: HTML

Abstract

Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. Toxicity was characterized by leukopenia, resulting in the hospitalization of one patient for a febrile incident, and superficial phlebitis. The results were similar to those of previous studies, in that among the 13 patients evaluable for response (six previously untreated with chemotherapy) there were no responses.